# Keya Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/keya-medical-technology-co

- Industry: Healthcare IT
- Headquarters: Beijing, China
- Website: www.keyamedical.com
- Total disclosed funding: $52M
- Latest round: Series C (Nov 10, 2020)
- Investors on record: 8

## About

Keya Medical Technology Co., Ltd. specializes in AI-driven, non-invasive diagnostic solutions for cardiovascular diseases, focusing on improving patient safety and reducing costs associated with diagnostics.Keya Medical Technology Co., Ltd. was founded in 2016 in Beijing, China, providing innovative AI-enabled solutions for cardiovascular diagnostics. The company has completed 5 deals, with the most recent funding round occurring on November 10, 2020, where it raised CNY 200 million in Series C funding led by IDG Capital, alongside investors including Alwin Capital, Source Code Capital, and Tasly Holding Group. CEO Liwei Wang has been at the helm since its inception, driving the company’s focus on advanced medical technologies.Keya Medical specializes in AI-enabled, non-invasive diagnostic solutions for coronary artery disease, primarily through its flagship product, DEEPVESSEL FFR. This software provides advanced fractional flow reserve analysis derived from coronary computed tomography angiograms (CCTA), facilitating a physiological assessment of coronary arteries. The DEEPVESSEL FFR product was CE-marked in 2018 and FDA-cleared in 2022, expanding its global reach across markets including the USA, Europe, China, and Singapore. Keya Medical serves hospitals, cardiac care centers, and medical practices aiming to improve patient outcomes with precise diagnostic assessments.Keya Medical generates revenue from the sale of its DEEPVESSEL FFR software, utilized by medical facilities focused on cardiovascular care. The company operates on a B2B transactional model, where healthcare institutions license the software and may pay annual subscriptions or one-time fees based on installations or users. The introduction of CPT code 75580 for non-invasive FFR estimates from coronary CT angiography is expected to facilitate reimbursement pathways, adding to the appeal of its products. Recent strategic initiatives have strengthened partnerships with healthcare organizations, supporting revenue growth.Keya Medical plans to utilize its recent CNY 200 million Series C funding, raised in November 2020, to support the development of new products and expansion into new markets. The company is focused on enhancing its AI-driven diagnostic solutions and aims to penetrate additional regions, specifically targeting North America and Europe by 2023. This funding will also assist in accelerating partnerships and collaborations with healthcare organizations to broaden its market presence.

## Funding rounds

- Series C, Nov 10, 2020, $30M — IDG Capital, Source Code Capital, Alwin Capital, Tasly Holding Group
- Series B, Aug 13, 2020, $22M — Kunlun Fund, Alwin Capital, Shanghai Growth Investment, Jiyuan Capital
- Series A, Dec 23, 2016 — Kunlun Fund, GX Capital

## Investors

- Kunlun Fund (https://capitalatlas.ai/funds/kunlun-fund) — Series A, Series B
- GX Capital (https://capitalatlas.ai/funds/gx-capital) — Series A
- Alwin Capital — Series B, Series C
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series B
- Jiyuan Capital (https://capitalatlas.ai/funds/jiyuan-capital) — Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series C
- Source Code Capital (https://capitalatlas.ai/funds/source-code-capital) — Series C
- Tasly Holding Group — Series C